secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001613103-23-000144
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q2 FY24 revenue up 5.3% to $7.984B; GAAP EPS $0.68, non-GAAP $1.25; raises FY24 guidance
--------------------------------------------------------------------------------

- Revenue $7.984B, +5.3% reported / +5.0% organic; GAAP net income $909M ($0.68 EPS) +113%; non-GAAP EPS $1.25.
- Cardiovascular revenue $2.923B (+5.9%); Neuroscience $2.288B (+4.7%); Medical Surgical $2.142B (+7.0%); Diabetes $610M (+9.7%).
- Raises FY24 organic revenue growth guidance to 4.75% (from 4.5%) and non-GAAP EPS guidance to $5.13–$5.19 (from $5.08–$5.16).
- FDA approvals for Aurora EV-ICD and Symplicity Spyral RDN; CE Marks for Evolut FX TAVR, Simplera CGM, PulseSelect PFA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/0001613103-23-000144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/mdt-20231121.htm
  HTML page:      https://secwatch.observer/filing/0001613103-23-000144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer